New sudan virus vaccine trial launches in healthy adults

NCT ID NCT07565090

First seen May 06, 2026 · Last updated May 06, 2026 · Updated 1 time

Summary

This early-stage study tests a new vaccine designed to prevent Sudan virus disease, a severe and often deadly illness. About 112 healthy adults aged 18 to 50 will receive either the vaccine or a placebo to check for safety and immune response. The goal is to see if the vaccine is safe and prompts the body to make protective antibodies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUDAN VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • George Washington University

    Washington D.C., District of Columbia, 20037, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Johnson County Clin-Trials

    Lenexa, Kansas, 66219, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.